Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS · Delayed Price · Currency is USD
0.0100
0.00 (0.00%)
May 27, 2026, 9:45 AM EST
Emmaus Life Sciences Revenue
Emmaus Life Sciences had revenue of $1.98M in the quarter ending March 31, 2026, a decrease of -17.62%. This brings the company's revenue in the last twelve months to $12.03M, down -27.33% year-over-year. In the year 2025, Emmaus Life Sciences had annual revenue of $12.45M, down -25.22%.
Revenue (ttm)
12.03M
Revenue Growth
-27.33%
P/S Ratio
0.06
Revenue / Employee
364.52K
Employees
33
Market Cap
701.88K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.45M | -4.20M | -25.22% |
| Dec 31, 2024 | 16.65M | -12.94M | -43.73% |
| Dec 31, 2023 | 29.60M | 11.21M | 60.94% |
| Dec 31, 2022 | 18.39M | -2.22M | -10.77% |
| Dec 31, 2021 | 20.61M | -2.56M | -11.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evofem Biosciences | 20.24M |
| SQZ Biotechnologies Company | 12.12M |
| Regenerative Medical Technology Group | 5.10M |
| Avenue Therapeutics | 1.40M |
| Halberd | 6.94K |
| Aibotics | 2.18K |
Emmaus Life Sciences News
- 11 days ago - Emmaus Life Sciences Reports Quarterly Financial Results - Business Wire
- 2 months ago - Emmaus Life Sciences Reports Annual Financial Results - Business Wire
- 5 months ago - Emmaus Life Sciences enters license, distribution agreement with NeoImmuneTech - TheFly
- 5 months ago - Emmaus Life Sciences Announces Strategic Transaction - Business Wire
- 11 months ago - Emmaus Life Sciences receives FDA approval for Endari label changes - TheFly
- 11 months ago - Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements - PRNewsWire
- 1 year ago - Emmaus Life Sciences Reports Improved Quarterly Financial Results - PRNewsWire
- 2 years ago - Emmaus Life Sciences appoints Willis Lee as CEO - TheFly